Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Maxcyte (MXCT) Revenue (2020 - 2025)

Historic Revenue for Maxcyte (MXCT) over the last 6 years, with Q3 2025 value amounting to $6.8 million.

  • Maxcyte's Revenue fell 1635.23% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $34.4 million, marking a year-over-year decrease of 2451.97%. This contributed to the annual value of $38.6 million for FY2024, which is 644.5% down from last year.
  • According to the latest figures from Q3 2025, Maxcyte's Revenue is $6.8 million, which was down 1635.23% from $8.5 million recorded in Q2 2025.
  • In the past 5 years, Maxcyte's Revenue registered a high of $15.7 million during Q4 2023, and its lowest value of $6.5 million during Q1 2021.
  • Its 5-year average for Revenue is $9.7 million, with a median of $9.6 million in 2022.
  • Per our database at Business Quant, Maxcyte's Revenue skyrocketed by 7840.61% in 2022 and then plummeted by 4450.69% in 2024.
  • Over the past 5 years, Maxcyte's Revenue (Quarter) stood at $10.2 million in 2021, then rose by 22.37% to $12.4 million in 2022, then increased by 26.1% to $15.7 million in 2023, then plummeted by 44.51% to $8.7 million in 2024, then dropped by 21.44% to $6.8 million in 2025.
  • Its Revenue was $6.8 million in Q3 2025, compared to $8.5 million in Q2 2025 and $10.4 million in Q1 2025.